Zymeworks Inc. (ZYME): Cash & Equivalents
$41.16M
As of 2025-12-31
$179.41M
As of 2026-06-30
-53.2%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $41.16M | -37.7% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $66.10M | -58.0% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $157.56M | -60.7% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $400.91M | +98.6% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $201.87M | n/a | 2023-03-07, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Zymeworks Inc. (ZYME) | 2025-12-31 | $41.16M | -37.7% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $62.41M | +84.7% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $110.75M | -35.6% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $37.07M | +213.8% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $154.97M | -0.3% |
| Xencor Inc (XNCR) | 2025-12-31 | $54.07M | +32.3% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $122.52M | +29.2% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.27M | -2.3% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $120.86M | -27.5% |
Compare ZYME, ZVRA, URGN, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗